Risk of Liver Fibrosis in Methotrexate-Treated Patients: A Systematic Review
Authors:
- Sumahitha BichenapallySBSumahitha Bichenapally
- Vahe KhachatryanVKVahe Khachatryan
- Asmaa MuazzamAMAsmaa Muazzam
- Chandani HamalCHChandani Hamal
- Lakshmi Sai Deepak Reddy VelugotiLVLakshmi Sai Deepak Reddy Velugoti
- Godfrey TaboweiGTGodfrey Tabowei
- Greeshma N. GaddipatiGGGreeshma N. Gaddipati
- Maria MukhtarMMMaria Mukhtar
- Mohammed J. AlzubaideeMAMohammed J. Alzubaidee
- Raga Sruthi DwarampudiRDRaga Sruthi Dwarampudi
- Safeera KhanSKSafeera Khan
Open Access
- 30 October 2022
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 14 (10) , e30910
Abstract
Methotrexate (MTX), an antifolate agent, is recommended as the first-line disease-modifying antirheumatic drug (DMARD). In this systematic review, our goals were to assess liver fibrosis in methotrexate-treated patients, evaluate liver fibrosis in relation to treatment duration and cumulative dose, and identify differences based on the underlying disease. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to perform the systematic review. We thoroughly searched PubMed, PubMed Central (PMC), and Cochrane library databases to identify relevant articles based on predefined selection criteria. Studies were selected based on the following predefined eligibility criteria: English language, papers from the last 20 years, systematic reviews, observational studies, randomized controlled trials (RCTs), and clinical trials, which included papers on MTX playing roles in the development of liver fibrosis with the derived data transferred to a template. Following that, quality was assessed using the appropriate assessment tool for each study. The initial search yielded 512 results. Following a thorough review, 10 studies were chosen for final consideration: eight observational studies and two systematic reviews. Liver enzyme (LE) elevations during MTX therapy are a common but transient problem. Serial abnormal LE tests may be associated with liver pathology, but fibrosis development is uncommon. However, it is unclear from the literature how therapy should be adjusted in the case of elevated LE and to what extent MTX is linked to liver toxicity; definitive conclusions cannot be drawn because more research is needed.Keywords
This publication has 25 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexateJoint Bone Spine, 2010
- Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapyRheumatology, 2008
- Diagnosis of liver fibrosis by transient elastography (FibroScan) and non‐invasive methods in Crohn's disease patients treated with methotrexateAlimentary Pharmacology & Therapeutics, 2006
- Psoriatic arthritis therapy: NSAIDs and traditional DMARDsAnnals of the Rheumatic Diseases, 2005
- Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational studyAnnals of the Rheumatic Diseases, 2003
- The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD coursesRheumatology, 2002
- Meta‐analysis of treatment termination rates among rheumatoid arthritis patients receiving disease‐modifying anti‐rheumatic drugsRheumatology, 2000
- Usefulness of the american college of rheumatology recommendations for liver biopsy in methotrexate‐treated rheumatoid arthritis patientsArthritis & Rheumatism, 1995
- Methotrexate induced liver cirrhosisBritish Journal of Dermatology, 1980